INTRODUCTION
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease caused by the accumulation of surfactant proteins and lipids in the alveoli, resulting in impairment of gas exchange [1, 2] . The incidence is believed to be 0.2 per million. PAP potentially stems from three different aetiologies which define three groups of patients: (a) congenital PAP, seen mainly in children; (b) secondary PAP, caused by a decrease in the number of alveolar macrophages and their function [1] ; and (c) acquired PAP, which is the predominant subtype of disease (almost 90% of cases), caused by acquired auto-antibodies against GM-CSF glycol-protein [2] . PAP usually presents with progressive exertional dyspnoea and non-productive cough with hypoxaemia. Some 20-31% of patients are asymptomatic. Clinical findings include inspiratory crackles (50%), cyanosis (25%) and digital clubbing (29-40%). Because these symptoms are non-specific, the average time to diagnosis is 7 months. Pulmonary function tests demonstrate hypoxia due to pulmonary shunting, and deranged CO diffusion. FEV1 values are usually normal in non-smoking PAP patients [1] . Imaging studies reveal bilateral infiltrates on chest x-ray, while CT scans show diffuse ground-glass opacities and air-space consolidation with interlobular septal thickening forming a 'crazy paving' pattern [1, 2] . Treatment for symptomatic PAP patients is based on whole lung lavage. Other treatments, effective in cases of acquired PAP, are inhalation or subcutaneous injection of GM-CSF and rituximab, and plasmapheresis [1, 2] . PAP itself, as a single morbidity, is considered to be a uncommon disease. Nonetheless, in rarer cases, it might present as a part of a syndrome (PAP, myelodysplastic syndrome (MDS) and recurrent miscarriages) associated with a mutation in the haematopoietic transcription factor gene GATA2 [3] . The following case presentation describes a patient suspected of, and clinically managed as having GATA2 mutationassociated PAP.
A diagnostic bronchoscopy was carried out when the patient was first hospitalized: alveolar spaces were found to be filled with a PASpositive, diastase-resistant acellular proteinaceous material with cholesterol clefts. The alveolar architecture was preserved, without signs of interstitial inflammation or fibrosis, in the lung tissue taken for microscopic examination. The combined macro-and microscopic findings were interpreted as consistent with pulmonary alveolar proteinosis (PAP). At the beginning of the patient's stay in our department, after consultation with a pulmonologist, and in face of accumulating clinical, radiographic and pathological findings, the diagnosis of PAP was made. Negative testing for anti-GM-CSF antibodies identified the condition as secondary PAP. The patient was referred for a whole lung lavage as a final diagnostic and potentially therapeutic intervention. Unfortunately, a peri-procedural stroke occurred and the patient was transferred to the neurological department for recovery.
DISCUSSION
The simultaneous presentation of secondary PAP, MDS and recurrent miscarriages, along with low monocyte and lymphocyte counts, led us on a quest for a single aetiology. PAP secondary to MDS was found to casually co-appear with Behçet's disease [4] , however our patient did not meet the clinical criteria for Behçet's. Her symptoms are highly suggestive of a single, loss of function GATA2 mutation which causes, via haplo-insufficiency, reduced production of a zinc-finger haematopoietic transcription factor [3] . The clinical, phenotypic presentation of GATA2 mutation is diverse. It includes immunodeficiency with marked propensity to infections (non-tuberculous mycobacterium, viral and fungal), predisposition to MDS, PAP, dermal pathology, malignancy (mainly viral related), vascular and lymphatic disease, sensorineural hearing loss, miscarriages and hypothyroidism. Laboratory findings reveal circulating monocytopaenia, dendritic cell cytopaenia, and B and NK cell lymphocytopaenia [3] . Haematopoietic cell transplantation has been performed successfully in six patients with GATA2 deficiency and resulted in reconstitution of the severely deficient lymphocyte populations and reversal of the clinical phenotype, including severe PAP [5] . Genetic testing for GATA2 mutation, necessitating full gene sequencing, was not accomplished in our patient. Nevertheless, and notwithstanding the fact that partial sequencing is currently negative, the clinical decision was to manage this patient as a GATA-mutation positive patient due to the high concordance with the clinical features of GATA-mutation positive related cases. After her neurological recovery the patient will be referred for bone marrow transplantation. SUMMARY PAP is a rare pulmonary disease that may occur in isolation or as part of a syndrome caused by a GATA2 mutation which also affects the haematopoietic and immune systems. Recognizing those patients with a GATA2 mutation among PAP patients will potentially enable better treatment options to be chosen and possible complications to be predicted.The simultaneous presentation of secondary PAP, MDS and recurrent miscarriages, along with low monocyte and lymphocyte counts, led us on a quest for a single aetiology. PAP secondary to MDS was found to casually co-appear with Behçet's disease [4] , however our patient did not meet the clinical criteria for Behçet's. Her symptoms are highly suggestive of a single, loss of function GATA2 mutation which causes, via haplo-insufficiency, reduced production of a zinc-finger haematopoietic transcription factor [3] . The clinical, phenotypic presentation of GATA2 mutation is diverse. It includes immunodeficiency with marked propensity to infections (non-tuberculous mycobacterium, viral and fungal), predisposition to MDS, PAP, dermal pathology, malignancy (mainly viral related), vascular and lymphatic disease, sensorineural hearing loss, miscarriages and hypothyroidism. Laboratory findings reveal circulating monocytopaenia, dendritic cell cytopaenia, and B and NK cell lymphocytopaenia [3] . Haematopoietic cell transplantation has been performed successfully in six patients with GATA2 deficiency and resulted in reconstitution of the severely deficient lymphocyte populations and reversal of the clinical phenotype, including severe PAP [5] .
